A trial of a new vaccine to treat throat cancer caused by a virus called human papillomavirus (REALISTIC)
Cancer type:
Status:
Phase:
This trial looked at a new vaccine called ADXS11 001. Researchers wanted to see if it was safe to use and could boost the immune system of people who had cancer of the part of the throat just behind the mouth (oropharyngeal cancer). This trial was supported by Cancer Research UK.
More about this trial
Some oropharyngeal cancers are caused by the 
(HPV). The vaccine ADXS11 001 was designed to boost the immune system of people with oropharyngeal cancer caused by HPV.
The vaccine was so new that the researchers didn’t know if it would work. So they needed to test it in a small number of people.
The main aims of this trial were to see if ADXS11 001 was safe to use and if it had an effect on the immune system.
Summary of results
This trial closed early after one person had developed a serious infection caused by the vaccine and the company who makes the vaccine decided not to continue supplying it for the study.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists () and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor Terence Jones
Supported by
Aintree University Hospitals NHS Foundation Trust
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
University of Liverpool
Other information
This is Cancer Research UK trial number CRUK/10/010
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
